Esperion Therapeutics (ESPR) Tops Q2 EPS by 15c

Esperion Therapeutics (NASDAQ: ESPR) reported Q2 EPS of ($0.46), $0.15 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $25.79 million versus the consensus estimate of $24.64 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• L3Harris CEO steps down amid conduct review, shares drop
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30